TRIlogy-4
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 400 patients (estimated)
- Tags
- Trispecific Antibody, B-Cell Maturation Antigen (BCMA), GPRC5D, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2228
- NCT Identifier
- NCT07258511
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.